Related Experiment Video

Updated: Nov 16, 2025

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.4K

Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein

Misha Mao1, Dengdi Hu2, Jingjing Yang1

  • 1Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Journal of Molecular Medicine (Berlin, Germany)
|February 21, 2021
PubMed

Insights

Placenta-specific 8 (PLAC8) influences tamoxifen resistance in estrogen receptor-positive breast cancer by affecting the MAPK/ERK pathway. Curcumin may offer therapeutic potential against tamoxifen failure by targeting PLAC8.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tamoxifen resistance is a significant challenge in estrogen receptor-positive breast cancer treatment.
  • Placenta-specific 8 (PLAC8) is linked to epithelial-mesenchymal transition and tumor development.
  • The precise role of PLAC8 in tamoxifen resistance is not fully understood.

Purpose of the Study:

  • To investigate the molecular mechanisms of PLAC8 in tamoxifen resistance.
  • To explore the potential of curcumin in overcoming tamoxifen resistance.
  • To evaluate PLAC8 as a potential therapeutic target.

Main Methods:

  • Utilized MCF-7 and tamoxifen-resistant breast cancer cell lines (MCF-7/TAM).
  • Investigated the role of PLAC8 in regulating drug sensitivity.
  • Examined the involvement of the MAPK/ERK pathway.

Main Results:

  • PLAC8 was found to regulate drug sensitivity in tamoxifen-resistant cells.
  • The MAPK/ERK pathway is implicated in PLAC8's function.
  • Curcumin demonstrated potential therapeutic effects.

Conclusions:

  • PLAC8 plays a role in tamoxifen resistance in breast cancer.
  • Targeting PLAC8, potentially with curcumin, may be a strategy against tamoxifen failure.
  • PLAC8 represents a potential druggable target for overcoming endocrine therapy resistance.
Keywords:
Breast cancer,Curcumin,MAPK/ERK pathway,PLAC8,Tamoxifen resistance,Ubiquitination

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.0K
An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

9.8K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K